scispace - formally typeset
L

Liang-In Lin

Researcher at National Taiwan University

Publications -  107
Citations -  5398

Liang-In Lin is an academic researcher from National Taiwan University. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 34, co-authored 105 publications receiving 4752 citations.

Papers
More filters
Journal ArticleDOI

Stability of curcumin in buffer solutions and characterization of its degradation products

TL;DR: It was shown that decomposition was pH-dependent and occurred faster at neutral-basic conditions and vanillin, ferulic acid, feruloyl methane were identified as minor degradation products and the amount of vanillin increased with incubation time.
Journal ArticleDOI

AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.

TL;DR: It is demonstrated that RUNX1 mutation was an independent poor prognostic factor for overall survival and associated with distinct biologic and clinical characteristics and poor prognosis in patients with de novo AML.
Journal ArticleDOI

DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications

TL;DR: The DNMT3A mutation may be a potential biomarker for monitoring of minimal residual disease and an independent poor prognostic factor for overall survival and relapse-free survival in total patients and also in normokaryotype group.
Journal ArticleDOI

Characterization of CEBPA Mutations in Acute Myeloid Leukemia: Most Patients with CEBPA Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic Cells

TL;DR: Most AML with CEBPA mutations were associated with an immunophenotype of HLA-DR+CD7+CD13+CD14−CD15+CD33+CD34+, which implicate theCEBPA mutation as a potential marker for monitoring minimal residue disease.
Journal ArticleDOI

Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution.

TL;DR: The findings that NPM mutations are stable during disease evolution and closely associated with disease status make it a potential marker for monitoring minimal residual disease.